New RNA-based Therapy Combats Melanoma in Mouse Models : vim

Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.

Related Keywords

Ohio , United States , Ohio State University , East Harlem , New York , American , Brian Brown , Yizhou Dong , Binbin Deng Ohio State University , Yonger Xue Ohio State University , National Institute , Icahn School Of Medicine At Mount Sinai , Astrazeneca , Shi Du Ohio State University , Icahn Genomics Institute , Merck Co , Davidw Mccomb Ohio State University , Professor Of Oncological Sciences , Jingyue Yan Ohio State University , Health System , Novo Nordisk , Yuebao Zhang Ohio State University , Chang Wang Ohio State University , Yichen Zhong Ohio State University , Association Of American Medical Colleges , Mount Sinai Health System , Dianad Kang Ohio State University , Xucheng Hou Ohio State University , National Institutes Of Health , National Cancer Institute , Icahn School , Mount Sinai , Nature Nanotechnology , Oncological Sciences , Icahn Mount , Associate Director , Cancer Immunity Cycle , Yuebao Zhang , Xucheng Hou , Icahn Mount Sinai , Yonger Xue , Jingyue Yan , Yichen Zhong , Chang Wang , Binbin Deng , General Medical Sciences , National Institutes , American Medical Colleges , Mount Sinai Innovation Partners , New York City , Upper East Side , Melanoma , Rna ,